4.6 Article

GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease

期刊

MOVEMENT DISORDERS
卷 31, 期 1, 页码 95-102

出版社

WILEY-BLACKWELL
DOI: 10.1002/mds.26359

关键词

cognition; GBA; neuropsychological tests; visuospatial; working memory

资金

  1. National Institutes of Health [K23 NS060949, P01 AG017586, P01 ES016732, P30 AG010124, P50 AG005136, P50 NS038367, P50 NS038377, P50 NS053488, P50 NS062684, R01 ES010544, R01 NS065070, U01 NS082133, U54 ES012078]
  2. Department of Veterans Affairs [1I01BX000531]
  3. Consolidated Anti-Aging Foundation
  4. Dolsen Foundation
  5. Jane and Lee Seidman Fund
  6. Nancy and Buster Alvord Endowment
  7. Parkinson's Disease Foundation
  8. Sartain Lanier Family Foundation
  9. Office of Research and Development Medical Research Service, Department of Veterans Affairs
  10. National Center for Complementary & Integrative Health [U01AT000613] Funding Source: NIH RePORTER
  11. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012078, R01ES010544, P01ES016732] Funding Source: NIH RePORTER
  12. NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH092735] Funding Source: NIH RePORTER
  13. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038367, U01NS082133, P50NS053488, U01NS052592, R01NS067525, U01NS082134, R01NS065070, K23NS060949, P50NS038377, P50NS062684, R37NS067525] Funding Source: NIH RePORTER
  14. NATIONAL INSTITUTE ON AGING [P50AG005136, U19AG024904, P30AG010124, P01AG017586, U01AG029213, P50AG005146, U01AG024904] Funding Source: NIH RePORTER
  15. NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER
  16. Veterans Affairs [I01BX000531] Funding Source: NIH RePORTER

向作者/读者索取更多资源

BackgroundLoss-of-function mutations in the GBA gene are associated with more severe cognitive impairment in PD, but the nature of these deficits is not well understood and whether common GBA polymorphisms influence cognitive performance in PD is not yet known. MethodsWe screened the GBA coding region for mutations and the E326K polymorphism in 1,369 PD patients enrolled at eight sites from the PD Cognitive Genetics Consortium. Participants underwent assessments of learning and memory (Hopkins Verbal Learning Test-Revised), working memory/executive function (Letter-Number Sequencing Test and Trail Making Test A and B), language processing (semantic and phonemic verbal fluency), visuospatial abilities (Benton Judgment of Line Orientation), and global cognitive function (MoCA). We used linear regression to test for association between genotype and cognitive performance with adjustment for important covariates and accounted for multiple testing using Bonferroni's corrections. ResultsMutation carriers (n=60; 4.4%) and E326K carriers (n=65; 4.7%) had a higher prevalence of dementia (mutations, odds ratio=5.1; P=9.7x10(-6); E326K, odds ratio=6.4; P=5.7x10(-7)) and lower performance on Letter-Number Sequencing (mutations, corrected P[P-c]=9.0x10(-4); E326K, P-c=0.036), Trail Making B-A (mutations, P-c=0.018; E326K, P-c=0.018), and Benton Judgment of Line Orientation (mutations, P-c=0.0045; E326K, P-c=0.0013). ConclusionsBoth GBA mutations and E326K are associated with a distinct cognitive profile characterized by greater impairment in working memory/executive function and visuospatial abilities in PD patients. The discovery that E326K negatively impacts cognitive performance approximately doubles the proportion of PD patients we now recognize are at risk for more severe GBA-related cognitive deficits. (c) 2015 International Parkinson and Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Clinical Neurology

Teaching NeuroImages: The dentate sign in subacute cerebellar ataxia Metronidazole neurotoxicity

Merida Teran Jimenez, Philippe Salles Gandara, Alberto J. Espay

NEUROLOGY (2023)

Article Clinical Neurology

Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases

Luca Marsili, Kevin R. Duque, Nathan Gregor, Elhusseini Abdelghany, Jesus Abanto, Andrew P. Duker, Matthew C. Hagen, Alberto J. Espay, Matteo Bologna

Summary: This study found no significant differences in the features of bradykinesia between patients with synucleinopathies and tauopathies.

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

Spectrum of Pediatric to Early Adulthood POLR3A-Associated Movement Disorders

Alonso Zea Vera, Adrienne Bruce, Travis R. Larsh, Zachary Jordan, Norbert Bruggemann, Ana Westenberger, Alberto J. Espay, Donald L. Gilbert, Steve W. Wu

Summary: POLR3A-related disorders exhibit significant phenotypic pleomorphism, including a range of movement disorders such as parkinsonism, dystonia, ataxia, and spasticity. Vertical gaze dysfunction and T2-weighted/FLAIR hyperintensity of the superior cerebellar peduncles and midbrain may be useful signs suggestive of this condition.

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Article Clinical Neurology

Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated

John L. Robinson, Sharon X. Xie, Daniel R. Baer, EunRan Suh, Vivianna M. Van Deerlin, Nicholas J. Loh, David J. Irwin, Corey T. McMillan, David A. Wolk, Alice Chen-Plotkin, Daniel Weintraub, Theresa Schuck, Virginia M. Y. Lee, John Q. Trojanowski, Edward B. Lee

Summary: In this retrospective study, the incidence of 10 pathologies in neurodegenerative disease (ND) and normal aging was examined, with up to seven pathologies observed concurrently resulting in 161 different combinations. The presence of multiple additive pathologies was associated with factors such as longer disease duration, clinical dementia, older age, and APOE e4 status.
Article Clinical Neurology

Redefining Bradykinesia

Matteo Bologna, Alberto J. Espay, Alfonso Fasano, Giulia Paparella, Mark Hallett, Alfredo Berardelli

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies

Danielle S. Abraham, Thanh Phuong Pham Nguyen, Leah J. Blank, Dylan Thibault, Shelly L. Gray, Sean Hennessy, Charles E. Leonard, Daniel Weintraub, Allison W. Willis

Summary: This study examined the differential prescribing patterns between new and established treatments for common neurological conditions. Using data from a national sample of US commercially insured adults from 2005-2019, the study compared new users of recently approved medications for three conditions: diabetic peripheral neuropathy, Parkinson disease psychosis, and epilepsy. The results showed that newer medications were more frequently prescribed to individuals with prior treatment, suggesting potential bias in comparative effectiveness and safety studies. The study emphasizes the importance of reporting propensity score non-overlap in comparative studies involving newer medications and suggests methodological approaches to address channeling bias.

NEUROTHERAPEUTICS (2023)

Editorial Material Clinical Neurology

Alpha-synuclein and the Parkinson's disease drug pipeline

Alberto J. Espay, Kevin McFarthing

Summary: The process of protein aggregation involves the transformation of soluble peptides into insoluble cross-beta amyloids. In Parkinson's disease, soluble monomeric a-synuclein transforms into the amyloid state known as Lewy pathology. Most disease-modifying projects in the therapeutic pipeline for Parkinson's disease aim to reduce the insoluble a-synuclein fraction, while none aim to increase soluble a-synuclein levels. We propose rebalancing the therapeutic pipeline to include treatments that restore soluble a-synuclein within a normal range.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

Digital Biomarkers in Parkinson's Disease: Missing the Forest for the Trees?

Ashwani Jha, Alberto J. Espay, Andrew J. Lees

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Review Clinical Neurology

Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis

Paula Saffie Awad, Daniel Teixeira-dos-Santos, Bruno Lopes Santos-Lobato, Sarah Camargos, Mario Cornejo-Olivas, Carlos Roberto de Mello Rieder, Ignacio F. Mata, Pedro Chana-Cuevas, Christine Klein, Artur F. Schumacher Schuh

Summary: This study conducted a systematic review and meta-analysis on genetic parkinsonism in Latin America, finding pathogenic variants in 19 different genes among Latin American patients. The frequency of pathogenic variants in LRRK2, PRKN, and GBA1 genes were 1.38%, 1.16%, and 4.17% respectively. Further research is needed in the region for better understanding and personalized therapies.

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial

Hubert H. Fernandez, Daniel Weintraub, Eric Macklin, Irene Litvan, Michael A. Schwarzschild, Jamie Eberling, Aleksandar Videnovic, Christopher J. Kenney

Summary: In patients with Parkinson disease dementia (PDD), SYN120 did not improve cognition significantly but showed potential benefits in cognitive activities of daily living and apathy.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

Potentially inappropriate medications in older adults with Parkinson disease before and after hospitalization for injury

Thanh Phuong Pham Nguyen, Shelly L. Gray, Craig W. Newcomb, Qing Liu, Ali G. Hamedani, Daniel Weintraub, Sean Hennessy, Allison W. Willis

Summary: This study found that there were no significant differences in medication prescriptions between Parkinson disease (PD) patients hospitalized for serious injury and those hospitalized for other reasons, indicating a missed opportunity to deprescribe high-risk medications during care transitions.

PARKINSONISM & RELATED DISORDERS (2023)

Letter Clinical Neurology

History of high household pesticide use and Parkinson's disease in Brazil

Dafne Dalledone Moura, Vanderci Borges, Henrique Ballalai Ferraz, Artur F. S. Schuh, Carlos Roberto de Mello Rieder, Ignacio F. Mata, Manuelina Mariana Capellari Macruz Brito, Vitor Tumas, Bruno Lopes Santos-Lobato

Summary: The prevalence of Parkinson's disease (PD) is increasing worldwide, and there may be a connection between household pesticide exposure and this trend. Our study revealed that individuals with high exposure to household pesticides have twice the risk of developing PD. Exposure to household pesticides does not affect the age at which PD symptoms appear.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP)

Vindhya Koneru, Alberto J. Espay, Allan J. Cole, Daniel Weintraub, Kathleen Crist, Maria B. Pascual, William G. Ondo

MOVEMENT DISORDERS (2023)

暂无数据